創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
21/11/12 GEM263 Viral RNA replication inhibitor Flaviviruses and Coronaviruses, including SARS-CoV-2 p.o. small molecule Preclinical GEM263 possessed both potent anti-flavivirus and anti-coronavirus activities at submicromolar levels without significant cytotoxicity.
GEM263 inhibited viral RNA replication and specifically inhibited replication at the late stages of the SARS-CoV-2 infection process. GEM263 5’-triphosphate inhibited RNA extension catalyzed by the viral RNA-dependent RNA-polymerase, too. GEM263 has the potential of serving as a lead compound for the development of a broad spectrum of antiviral agents, including SARS-CoV-2.
問合せ
21/11/12 GEM262 Anti-Inflammatory Drug derived from Resolvin E2 SLE, IBD,RA,Psoriasis, Pain p.o. small molecule Preclinical The anti-inflammatory effects of Resolvin E2 are even more potent than clinically effective steroidal and nonsteroidal anti-inflammatory drugs.
GEM262 is a new stable compound as an equivalent of Resolvin E2 and promotes the resolution of inflammation by inhibiting neutrophil infiltration and promotion phagocytosis of macrophages in remarkably low doses.
問合せ
21/11/12 GEM261 A novel PPM1D inhibitor Cancer p.o. small molecule Preclinical Protein phosphatase Magnesium-dependent 1, Delta (PPM1D)/ Wip1 is a wild-type p53-inducible Ser/Thr phosphatase that acts as a negative regulator of the p53 tumor suppressor. Gene amplification and overexpression of PPM1D have been reported in various cancers including leukemia and neuroblastoma.
A novel PPM1D/WIP1 inhibitor suppresses medulloblastoma and neuroblastoma growth in vivo.
問合せ
21/11/12 GEM260 A novel protein that regulates bone metabolizing cells Osteoporosis Injection Protein Preclinical GEM260 with a novel mechanism for the treatment of bone loss diseases. The GEM260 potently suppresses the induction of osteoclast differentiation and bone resorption, and enhances the expression of osteoblast anabolic factors to promote bone formation in vitro. Evaluation of the therapeutic effect of GEM260 in osteoporosis OVX and calvarial models and inflammatory osteolysis model is currently underway. 問合せ
21/11/12 GEM259 A novel peptide targeting a STAP-2-EGFR Prostate cancer, Breast cancer i.v. Peptide Preclinical STAP-2 belongs to a family of STAP adaptor proteins and plays a crucial role in a variety of cellular signal transduction pathways. STAP‐2 is expressed in various cancer cell lines and the expression level is higher than normal cells.
The inhibition of STAP-2 and EGFR interaction could be a novel target for the treatment of cancer. A novel peptide inhibiting STAP-2/EGFR interaction shows anti-tumor efficacy in vitro and in vivo.
問合せ
21/11/12 GEM258 A novel Peptide Targeting a STAP-2-TCR (T cell receptor) Autoimmune disease i.v. Peptide Preclinical STAP-2 belongs to a family of STAP adaptor proteins and plays a crucial role in a variety of cellular signal transduction pathways, in particular, regulates both the innate and adaptive immune systems.
STAP-2 is involved in the initiation of TCR signaling by forming a trimeric complex with LCK and CD3ζ.
Peptidic GEM258 binding ITAM motif in STAP-2 inhibits the T cell proliferation and T lymphoma proliferation in vitro and improved the EAE (experimental autoimmune encephalomyelitis) pathological score in vivo.
問合せ
21/11/12 GEM257 Promotion of Axon regeneration Disease with nerve damage Injection Protein
Preclinical GEM257 accelerated the rate of axonal regeneration (in vitro and in vivo), thereby restoring sensory function and tibialis anterior muscle function in vivo.
GEM257 can use as a nerve regeneration drug (local injection) for peripheral and central nerve damage and nerve regeneration inducer at combination with nerve regeneration inducing materials and regenerative medicine using autologous cells.
問合せ
21/10/12 GEM256 Stem cell repairing Osteoarthritis Intraーarticular Peptide Preclinical Synthetic novel PEDF-derived short peptide that stimulates cartilage regeneration morphology and pain relief efficacy (MIA-induced model, medial meniscal transection (MMT) model).
Long patent protection.Available for licensing globally.
問合せ
21/10/12 GEM255 Stem cell repairing Neurotropic keratitis Topical (eye drop) Peptide Phase 1 Synthetic novel neurotrophic PEDF-derived short peptide that stimulates wound healing and corneal repair. Effectively regenerate healthy limbus after extensive limbal layer removal (Rabbit Model)
Long patent protection.Available for licensing globally.
問合せ
21/10/12 GEM254 Stem cell repairing Dry eye syndrome Topical (eye drop) Peptide Phase 2 Synthetic PEDF-derived short peptide to stimulate proliferation and differentiation of corneal limbal stem cells to speed up cornea repair process. Repair severe cornea damages for patients
lacking treatment options.
The Phase 2 studies demonstrated that GEM254 is safe, effective, and the results are reproducible.
Long patent protection.
Available for licensing globally excluding China.
問合せ